S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Scholar Rock Stock Price, News & Analysis (NASDAQ:SRRK)

$18.25
+0.70 (+3.99%)
(As of 12/8/2023 ET)
Compare
Today's Range
$17.88
$19.53
50-Day Range
$6.52
$18.25
52-Week Range
$5.56
$19.53
Volume
1.68 million shs
Average Volume
725,535 shs
Market Capitalization
$1.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.75

Scholar Rock MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
35.6% Upside
$24.75 Price Target
Short Interest
Bearish
14.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.34mentions of Scholar Rock in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$30.09 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.96) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

297th out of 933 stocks

Biological Products, Except Diagnostic Industry

50th out of 160 stocks


SRRK stock logo

About Scholar Rock Stock (NASDAQ:SRRK)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

SRRK Stock Price History

SRRK Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Scholar Rock (NASDAQ:SRRK) Shares Gap Up to $17.55
Scholar Rock (NASDAQ:SRRK) Sets New 1-Year High at $13.64
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Scholar Rock Holding Insider Trades Send a Signal
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRK
Employees
114
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.75
High Stock Price Target
$30.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+35.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-134,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$33.19 million
Book Value
$5.04 per share

Miscellaneous

Free Float
53,242,000
Market Cap
$1.32 billion
Optionable
Not Optionable
Beta
0.66
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Jay T. Backstrom M.D. (Age 68)
    M.P.H., President, CEO & Director
    Comp: $686.49k
  • Mr. Edward H. Myles MBAMr. Edward H. Myles MBA (Age 51)
    CFO, COO & Treasurer
    Comp: $668.49k
  • Ms. Junlin Ho J.D. (Age 44)
    General Counsel & Corporate Secretary
    Comp: $563.73k
  • Ms. Catherine Hu
    Vice President of Investor Relations & Corporate Communications
  • Ms. Caryn Parlavecchio (Age 51)
    Chief Human Resources Officer
  • Ms. Lisa Amaya Price
    Senior Vice President of Human Resources
  • Ms. Erin Moore (Age 48)
    Senior Vice President of Finance
  • Mr. Ryan Iarrobino
    Senior Vice President of Clinical Development & Operations
  • Dr. Jing L. Marantz M.B.A. (Age 58)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Tracey M. Sacco M.B.A. (Age 47)
    Chief Commercial Officer














SRRK Stock Analysis - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings
or view top-rated stocks.

What is Scholar Rock's stock price target for 2024?

4 analysts have issued 1-year price objectives for Scholar Rock's shares. Their SRRK share price targets range from $20.00 to $30.00. On average, they anticipate the company's stock price to reach $24.75 in the next year. This suggests a possible upside of 35.6% from the stock's current price.
View analysts price targets for SRRK
or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2023?

Scholar Rock's stock was trading at $9.05 at the beginning of 2023. Since then, SRRK stock has increased by 101.7% and is now trading at $18.25.
View the best growth stocks for 2023 here
.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our SRRK earnings forecast
.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). During the same quarter last year, the business earned ($0.55) earnings per share.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.24%), Redmile Group LLC (8.42%), Polar Capital Holdings Plc (2.08%), Laurion Capital Management LP (0.98%), Northern Trust Corp (0.73%) and TD Asset Management Inc (0.60%). Insiders that own company stock include Amir Nashat, Caryn Parlavecchio, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman, Mo Qatanani, Public Equities LP Invus and Samsara Biocapital Gp, Llc.
View institutional ownership trends
.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SRRK) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -